TY - JOUR
T1 - Cardiovascular involvement in patients affected by acromegaly
T2 - An appraisal
AU - Mosca, Susanna
AU - Paolillo, Stefania
AU - Colao, Annamaria
AU - Bossone, Eduardo
AU - Cittadini, Antonio
AU - Iudice, Francesco Lo
AU - Parente, Antonio
AU - Conte, Sirio
AU - Rengo, Giuseppe
AU - Leosco, Dario
AU - Trimarco, Bruno
AU - Filardi, Pasquale Perrone
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Cardiovascular complications are frequent in acromegalic patients. Several studies reported increased prevalence of traditional cardiovascular risk factors and early development of endothelial dysfunction and of structural vascular alterations, with subsequent increased risk of coronary artery disease. Furthermore, chronic exposure to high levels of GH and IGF-I leads to the development of the so called "acromegalic cardiomyopathy", characterized by concentric biventricular hypertrophy, diastolic dysfunction and, additionally, by progressive impairment of systolic performance leading to overt heart failure. Cardiac valvulopathies and arrhythmias have also been documented and may concur to the deterioration of cardiac function. Together with strict control of cardiovascular risk factors, early control of GH and IGF-I excess, by surgical or pharmacological therapy, has been reported to ameliorate cardiac and metabolic abnormalities, leading to a significant reduction of left ventricular hypertrophy and to a consistent improvement of cardiac performance.
AB - Cardiovascular complications are frequent in acromegalic patients. Several studies reported increased prevalence of traditional cardiovascular risk factors and early development of endothelial dysfunction and of structural vascular alterations, with subsequent increased risk of coronary artery disease. Furthermore, chronic exposure to high levels of GH and IGF-I leads to the development of the so called "acromegalic cardiomyopathy", characterized by concentric biventricular hypertrophy, diastolic dysfunction and, additionally, by progressive impairment of systolic performance leading to overt heart failure. Cardiac valvulopathies and arrhythmias have also been documented and may concur to the deterioration of cardiac function. Together with strict control of cardiovascular risk factors, early control of GH and IGF-I excess, by surgical or pharmacological therapy, has been reported to ameliorate cardiac and metabolic abnormalities, leading to a significant reduction of left ventricular hypertrophy and to a consistent improvement of cardiac performance.
KW - Acromegalic cardiomyopathy
KW - Acromegaly
KW - GH/IGF-I excess
KW - Premature atherosclerosis
UR - http://www.scopus.com/inward/record.url?scp=84883277849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883277849&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2012.11.109
DO - 10.1016/j.ijcard.2012.11.109
M3 - Article
C2 - 23219077
AN - SCOPUS:84883277849
VL - 167
SP - 1712
EP - 1718
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 5
ER -